Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
NEW YORK, Oct. 03, 2016 -- EMBER THERAPEUTICS (OTCQB:EMBT), today announced that Olympic Gold Medalist Ryan Lochte has signed an endorsement agreement with the company. Lochte, one of the stars of Team USA, has won 12 Olympic medals, including six gold medals, three silver medals and three bronze medals making him one of the most decorated swimmers in Olympic history.
The University of Florida graduate swam his way to victory countless times as a member of the Florida Gators swimming team, and was named NCAA Swimmer of the Year twice. He also became a seven-time NCAA champion, a seven-time SEC champion and a 24-time All-American. Lochte, who was born in Rochester New York, is currently a contestant on the Emmy nominated Dancing with the Stars.
“Ember Therapeutics’ Migralex is one of the top names in over the counter pain and headache relief and I’m thrilled to be in partnership with them,” said Lochte.
“Ryan Lochte has had an outstanding athletic career,” said Joseph Hernandez, Executive Chairman of Ember Therapeutics, Inc., “We are honored to have him be our spokesperson for Migralex, the only over the counter pain medicine containing Magnesium, which is easier on the stomach and further enhances the drug’s ability to deal with difficult headaches and most types of pain.”
As a result of over 25 years of research, a world renowned neurologist has developed and patented a breakthrough headache medicine that has been clinically proven to be highly effective in relieving most types of pain, including arthritis pain, tension headaches, sinus headaches, stress headaches, menstrual headaches, and various other pains.
Migralex™ is a patented product and is the strongest combination pain medicine available without a prescription. Its special rapid release formula gives fast acting relief, and is gentle on the stomach. Migralex™ reduces side effects common with other OTC pain relievers. It contains no caffeine, sodium or preservatives, and contains magnesium as a buffering agent.
Migralex™ is currently available at CVS, local pharmacies, online at Amazon.com and the product website www.migralex.com. To learn more about Migralex™ please access www.migralex.com.
About Ember Therapeutics, Inc.
Ember Therapeutics, Inc. is a diversified pharmaceutical company commercializing and developing targeted therapies for pain, osteoarthritis, kidney fibrosis and other regenerative medicines. In particular, Ember Therapeutics, Inc. has several commercial stage products and two late stage Phase 3 ready assets. For more information, please visit www.embertx.com.
Contact Information: Betty Rose (investors) (646) 406-6243 [email protected]
